secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001789769-25-000092
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio reports Q3 net loss $2.01/share; first patient dosed in Phase 1 trial of AXN-2510
--------------------------------------------------------------------------------

- Cash position $83.4M as of Sept 30, 2025, down from $115.1M at Dec 31, 2024; expects runway beyond 2026.
- First patient dosed in Phase 1 trial of AXN-2510/IMM2510 monotherapy in advanced solid tumors in October 2025.
- R&D expenses $9.1M in Q3 2025 vs $0.6M in Q3 2024; reflecting increased clinical activity.
- Net loss per share (GAAP) $2.01 in Q3 2025 vs $3.54 in Q3 2024; non-GAAP net loss $1.75 vs $2.55.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/0001789769-25-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000092/til-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer